^
    Back
    Association details:
    Biomarker:MYD88 mutation + CXCR4 mutation
    Cancer:Waldenstrom Macroglobulinemia
    Drug:Imbruvica (ibrutinib) (BTK inhibitor) +
    mavorixafor (X4P-001) (CXCR4 antagonist)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASH 2021
    Title:

    Preliminary Clinical Response Data from a Phase 1b Study of Mavorixafor in Combination with Ibrutinib in Patients with Waldenström’s Macroglobulinemia with MYD88 and CXCR4 Mutations

    Published date:
    11/04/2021
    Excerpt:
    This is an ongoing phase 1b, open-label, multicenter, single-arm study (NCT04274738) examining mavorixafor in combination with ibrutinib...Four of 8 patients achieved major response; 1 of 8 patients achieved very good partial response....These ongoing studies support the feasibility of combining ibrutinib with mavorixafor to improve responses in MYD88 CXCR4WHIM WM.
    DOI:
    10.1182/blood-2021-144706